

Catalog Number: CM06871

产品信息

Catalog Number:
CM06871

CAS号:
204005-46-9


分子式:
C₁₅H₁₄N₂O

主要靶点:
VEGFR

主要通路:
蛋白酪氨酸激酶|血管生成

分子量:
238.28

溶解度:
DMSO:2.38 mg/mL (10 mM)



靶点活性

VEGFR2:1.23 μ M

体外活性

SU5416 inhibits VEGF-driven mitogenesis in a dose-dependent manner with an IC₅₀ of 0.04±0.02 μ M (n=3). In contrast, SU5416 blocked FGF-dependent mitogenesis of HUVECs with an IC₅₀ of 50 μ M (n=10). The selective activity of SU5416 on Flk-1 is supported by the fact that testing of SU5416 using NIH 3T3 cells overexpressing either the EGF or insulin receptors indicated a complete lack of activity (IC₅₀>100 μ M). This observation is confirmed by immunoblotting after ligand stimulation. An IC₅₀ of 20.26±5.2 μ M (n=7), which is about 20-fold less in potency on PDGF-dependent autophosphorylation, is observed when SU5416 is tested in NIH 3T3 cells overexpressing the human PDGF receptor β [1].

体内活性

Daily administration of SU5416 (i.p., 3 mg/kg/day) inhibits the local growth of C6 tumors in the colon. A comparable level of growth inhibition (62% by day 16; P=0.001) is observed for tumors growing in the colon in comparison with ones growing in the hindflank region (54% by day 18; P=0.001). These results indicate that SU5416 could inhibit tumor growth at a site other than the subcutaneous implantation site, where the preexisting vasculature may be different [1]. Daily treatment with SU5416 (25 mg/kg) results in a significantly lower tumor growth rate with tumor masses of up to 8% of that present in control animals by day 22 after implantation. Inhibition of tumor growth is clearly preceded by a marked reduction of the tissue area covered by the newly formed glioma microvasculature in the SU5416-treated group, indicating a reduced initial tumor vascularization [2].

细胞实验

SU5416 is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO<0.5%) before use [1]. 3T3Her2 and 488 g2M2 are NIH3T3 fibroblast cell lines engineered to overexpress Her2 and to express human PDGF-BB and human PDGF receptor β . Both cell lines are cultured in DMEM supplemented with 2% CS and 2 mM L-glutamine. C6, Calu 6, A375, A431, and SF767T are plated in their respective growth medium at 2×10³ cells/100 μ L/well in 96-well, flat-bottomed plates. SU5416 is serially diluted in media containing DMSO (<0.5%) and added to cultures of tumor cells 1 day after the initiation of culture. Cell growth is measured after 96 h using the sulforhodamine B method. IC₅₀s are calculated by curve fitting using four-parameter analysis [1].

储存

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.